Five-year outcomes from the randomised SPACE-2 trial on carotid artery stenosis, an interview with Joseph S Coselli, and a report on the “significant” increase in atherectomy use in the USA caught readers’ attention in October.
Five-year outcomes of a multicentre, randomised controlled trial (RCT) indicate that carotid endarterectomy (CEA) or carotid artery stenting (CAS) are not superior to best medical therapy (BMT) alone for moderate-to-severe asymptomatic carotid artery stenosis.
Cordis recently announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance. A press release notes that the agreement includes an initial investment of US$35 million and US$200 million payment upon closing in 2023, regulatory achievement milestones up to US$125 million and commercial milestones up to US$775 million through 2029. Cordis will immediately begin co-promotion of MedAlliance’s Selution SLR drug-eluting balloon in markets where it is commercially available.
Joseph S Coselli (Baylor College of Medicine, Houston, USA) speaks to Vascular News about his career to date. Despite initially planning to follow in his family’s footsteps and attend law school, a summer internship at the Texas Heart Institute in Coselli’s native Houston changed the course of his career forever. The internship sparked an interest in cardiovascular surgery that would culminate in his current roles as professor of Surgery and executive vice chair of the Michael E DeBakey Department of Surgery at Houston’s Baylor College of Medicine, among others. Coselli has received widespread recognition for his work in cardiovascular and aortic surgery, and credits his success in large part to the important role of three celebrated mentors—Michael E DeBakey, Denton A Cooley and E Stanley Crawford.
Six-month data from the Surmodics SWING first-in-human (FIH) study of the company’s Sundance sirolimus drug-coated balloon (DCB) were shared at the 2022 Amputation Prevention Symposium (AMP; 9–11 October, Lugano, Switzerland).
Medtronic has announced the 36-month final results from the ABRE clinical study. The purpose of the ABRE clinical study was to evaluate the safety and effectiveness of the company’s Abre venous self-expanding stent system, intended for the treatment of symptomatic iliofemoral venous outflow obstruction.
A software named PRAEVAorta (Nurea), using artificial intelligence (AI), has the potential to enable a fast, reproducible, and fully automated analysis of abdominal aortic aneurysm (AAA) sac pre- and post-endovascular aneurysm repair (EVAR). This is according to Caroline Caradu (Bordeaux University Hospital, Bordeaux, France) and colleagues, who recently reported the results of a single-centre, retrospective analysis of fully automatic volume segmentation using deep learning approaches in the Journal of Vascular Surgery (JVS).
Thomas Rand (Klinik Florisdorf, Vienna, Austria) recently presented on the preliminary results to 12 months of the Motiv bioresorbable scaffold (Reva Medical) postmarket trial at the recent Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting (10–14 September, Barcelona, Spain).
W L Gore & Associates (Gore) has announced the completion of target enrolment in the EXPAND postmarket Registry of the Gore Viabahn VBX balloon-expandable endoprosthesis (VBX stent graft).
In the USA, atherectomy use in peripheral vascular interventions (PVIs) “more than doubled” from 2010 to 2019, with office-based procedures a “major driver” of this increase. This is according to published US data from the Vascular Quality Initiative (VQI), which also revealed wide regional variability in the use of atherectomy.
In a recently published study, the introduction of endovascular aneurysm repair (EVAR) into the management of ruptured abdominal aortic aneurysm (AAA) decreased the 30-day mortality in unstable patients. Authors Melissa Jones (Peter Lougheed Centre, Calgary, Canada) and colleagues write that such an emergency EVAR protocol “should be considered the first-line intervention for the appropriate patient”.